Company Filing History:
Years Active: 2022-2024
Title: Jason Boer: Innovator in FGFR Inhibitor Research
Introduction
Jason Boer is a notable inventor based in Landenberg, PA (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of Fibroblast Growth Factor Receptor (FGFR) inhibitors. With a total of 2 patents, his work is pivotal in advancing treatments for diseases mediated by FGFR, including various forms of cancer.
Latest Patents
Jason Boer's latest patents focus on derivatives of FGFR inhibitors. These derivatives include hydroxyl, keto, glucuronide, sulfonic acid, and deuterated forms. The disclosures detail methods of preparation and intermediates that are essential for the effective treatment of FGFR-mediated diseases. His innovative approach aims to enhance the efficacy of existing therapies and provide new avenues for cancer treatment.
Career Highlights
Jason Boer is currently employed at Incyte Corporation, where he continues to push the boundaries of pharmaceutical research. His work at Incyte has allowed him to collaborate with leading experts in the field and contribute to groundbreaking advancements in cancer treatment.
Collaborations
One of his notable collaborators is Ming Tao, with whom he has worked closely on various projects related to FGFR inhibitors. Their combined expertise has led to significant progress in the development of new therapeutic options.
Conclusion
Jason Boer is a dedicated inventor whose work on FGFR inhibitors is making a meaningful impact in the fight against cancer. His innovative research and collaborations are paving the way for future advancements in medical treatments.